Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02180724 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
A Phase 2 study of Waldenström Macroglobulinemia (WM), sponsored by Acerta Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT02180724: Active Phase 2 study of Waldenström Macroglobulinemia (WM), sponsored by Acerta Pharma.
NCT02180724 is a Phase 2 study of Waldenström Macroglobulinemia (WM) that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 107 participants. The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02180724, a Phase 2 study of Waldenström Macroglobulinemia (WM), is active but no longer recruiting, sponsored by Acerta Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
Conditions Studied
Interventions
- DRUG Acalabrutinib (ACP-196)
Study Locations (20)
Other
- Research Site - Aurillac
- Research Site - Clermond Ferrand
- Research Site - Marseille
- Research Site - Montpellier
- Research Site - Nantes
- Research Site - Paris
- Research Site - Paris
- Research Site - Pierre-Bénite
- Research Site - Poitiers
- Research Site - Reims
Texas
- Research Site - Austin
- Research Site - Bedford
- Research Site - Houston
California
- Research Site - Santa Barbara
Colorado
- Research Site - Aurora
District of Columbia
- Research Site - Washington D.C.
Minnesota
- Research Site - Minneapolis
New York
- Research Site - New York
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2014-09-11 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02180724
The ClinicalTrials.gov registry entry for NCT02180724 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Waldenström Macroglobulinemia (WM) appearing as the primary indexed condition, and to 1 intervention - of which Acalabrutinib (ACP-196) is the first listed.
NCT02180724 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT02180724 about?
NCT02180724 is a clinical study titled "An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia". The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and activity of acalabrutinib in treating subjects with WM.
What is the current status of trial NCT02180724?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2014-09-11. Estimated completion is 2026-12-31.
What conditions does trial NCT02180724 study?
This clinical trial studies the following conditions: Waldenström Macroglobulinemia (WM).
What interventions are being tested in trial NCT02180724?
The interventions under investigation include: Acalabrutinib (ACP-196) (DRUG).
Who is sponsoring clinical trial NCT02180724?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02180724 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.